Role of regulatory T-cells in Hansen's disease: A systematic review
Abstract
Leprosy represents a significant challenge in understanding the multiple immunological mechanisms that influence the distinct clinical forms. This integrative review used the electronic databases MEDLINE/PubMed and the Virtual Health Library (VHL), including 12 studies conducted predominantly in Brazil, China, India, and Ethiopia. We focused on the role of regulatory T (Treg) cells in Hansen's disease, specifically examining their frequency of expression and the functional characteristics of their subpopulations. Findings reveal the ubiquitous nature of Treg across clinical forms, particularly the CD3+CD4+CD25+FoxP3+ phenotype, with a pronounced frequency in multibacillary cases, including borderline-lepromatous and lepromatous leprosy. In these cases, a notable upregulation of inhibitory molecules (CTLA-4, PD-1) and the production of immunoregulatory cytokines (IL-10, TGF-β) are evident in skin lesions and/or in vitro-cultured cells. The intricate interplay of local stimuli, cytokine profiles, antigenic nature, receptor expressions, co-inhibitory molecules, and macrophage types modulates the cellular immune response, influencing disease severity. The increased presence of Treg and their associated products appears to contribute to bacillary multiplication in patients with the disseminated form, fostering disease persistence. This comprehensive review enhances our understanding of Hansen's disease pathogenesis, shedding light on potential avenues for targeted therapeutic…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.